Rezolute Announced Results From Preclinical Pharmacology Study That Validate The Potential For Its Lead Clinical Compound, RZ358, To Treat Individuals With Non-Islet Cell Tumors That Have Uncontrolled Hypoglycemia
Benzinga Newsdesk - Mar 6, 2024, 7:38AM